ESR1 and ovarian carcinoma: Kaplan–Meier survival analysis revealed a longer progression-free survival (PFS) and overall survival (OS) in ovarian cancer patients with low PAPSS1 expression and high ESR1 expression than those with low ESR1 and high PAPSS1(Fig. 6A).